Case 4: Treating Platinum-Resistant Recurrent Disease
Watch
Case 4: I-O Therapy for Platinum-Resistant Recurrent Disease
Case 4: Recurrent Ovarian Cancer, Platinum-Resistant, BRCA WT
Case 3: Selecting Therapy For Recurrent Disease
Case 3: PARP Inhibition in Recurrent Ovarian Cancer
Case 3: Molecular Testing in Recurrent Ovarian Cancer
Case 3: Recurrent Ovarian Cancer, Platinum-Sensitive, BRCA WT
Case 2: Olaparib in BRCA-Mutated Ovarian Cancer
Case 2: Treating BRCA-Mutated Ovarian Cancer
Case 2: Primary Treatment Options
Case 2: Newly Diagnosed Ovarian Cancer, gBRCA-Mutated
Case 1: Bevacizumab in Stage IV Ovarian Cancer
Case 1: Considerations for Neoadjuvant Therapy
Case 1: Considerations for Debulking Surgery
Case 1: Stage IV Ovarian Cancer With Multiple Metastatic Sites
Advanced Ovarian Cancer
HER2+ Breast Cancer: Managing Patients on T-DM1
Benefit of Antibody Drug Conjugate T-DM1 in HER2+ BC
Improving Long-Term Outcomes in HER2+ Breast Cancer
Case Review: T-DM1 for Residual HER2+ Breast Cancer
HER2+ BC: Residual Disease After Neoadjuvant Therapy
Analyzing Necessary Steps for Treating Patients with mCRC
Bassel El-Rayes, MD, discusses the key points physicians should consider when treating a patient with metastatic colorectal cancer.
The Future of Early HER2-Positive Management
The APHINITY Trial Regimen Efficacy & Toxicity Profile
Decision Factors for Choosing Early HER2-Positive Therapy
A 52-Year-Old Woman With HER2-Positive Breast Cancer
Early HER2+ Breast Cancer
Using Monoclonal Antibody Therapy in Multiple Myeloma
The GRIFFIN Trial in Multiple Myeloma
Monoclonal Antibody Therapy in the Frontline for Multiple Myeloma